כמות מזומנים למניה Kalaris Tx (KLRS)

סמל ולוגו של המותג kalaristx.com (KLRS)

Kalaris Therapeutics Inc (KLRS) is a reputable developer of ophthalmological anti-VEGF molecules, creating extended-release therapies for retinal dystrophy to reduce injection frequency. The cash per share dynamics for the stock demonstrate current liquidity, where the metric stands at 3.75. The brand's prospects rely on the success of clinical trials, which necessitates strict control over working capital expenditures.

יתרות מזומנים למניה Kalaris Therapeutics, Inc. (KLRS): לתקופה 20.03.2025 - 21.11.2026

פילוחים אנליטיים של חברת Kalaris Therapeutics Inc (KLRS)

- מחיר ותחזית קונצנזוס למחירים:
- נתוני מזומנים ותזרימי מזומנים:
ניתוח מסכם של החברה:Kalaris Therapeutics, Inc. - KLRS
סחורת הדגל של Kalaris Tx

The indicator is calculated as the ratio of total liquid assets to the number of shares outstanding. This metric determines the internal financial reserve available to cover expenses promptly without incurring external debt. For Kalaris Therapeutics Inc (KLRS), such funds are critical when implementing AI and the robotization of laboratory processes. The trend of cash per share for the issuer allows for an assessment of the sustainability of development automation rates. Analysis of this chart helps the investor forecast the company's autonomous operational horizon.